Review article: Zambia's foreign policy: themes and approaches
Marcia Burdette Zambia: Between Two Worlds Boulder: Westview Press, 1988. Stephen Chan Kaunda and Southern Africa: Image and Reality in Foreign Policy London: British Academic Press, 1992. Timothy Shaw and Douglas Anglin Zambia's Foreign Policy; Studies in Diplomacy and Dependency Boulder: Westview Press, 1979.
DILEMMAS OF POSTCOLONIAL DIPLOMACY: ZAMBIA, KENNETH KAUNDA, AND THE MIDDLE EAST CRISIS, 1964–73
Abstract This article examines Zambia's engagement with the Middle East conflict from 1964–73 as a window into the political strategies and ideological ambitions of Kaunda's government in the first decade of independence. At the start of independence, Kaunda's domestic agenda led him to establish ties with Israel and to advance a program for cooperative development based on Israeli technical assistance. However, broader international concerns, filtered through the struggle against white minority regimes in southern Africa, ultimately led Kaunda to embrace a leadership role in international protests against Israel's policies towards its neighboring states. Zambia's foray into Middle East diplomacy in the first decade of independence enables a focused examination of Kaunda's presence in the international arena, while also revealing the compromises he made in the face of conflicting interests. Zambia's role in the Middle East conflict highlights this era as a time of confidence and claim-making by African leaders, but also one of concessions.
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.